Recent technological advancements in genetic testing and the growing accessibility of public genomic data provide researchers with a unique avenue to approach personalized medicine. This study examined the potential of direct-to-consumer (DTC) genomic tests (focusing on 23andMe) in research and clinical applications. In particular, groups within the population were clustered by individual genetic information from the Personal Genome Project, on which association studies could be performed. The genetic information was then combined with adverse event reports from AEOLUS and pharmacogenomic information from PharmGKB. Primarily, associations between drugs based on co-occurring genetic variations and associations between variants and adverse events were used to assess the potential for leveraging single nucleotide polymorphism information from 23andMe. The results of this study suggest potential clinical uses of DTC tests in light of potential drug interactions. Furthermore, the results reveal great potential for analyzing associations at a population level to facilitate knowledge discovery in the realm of predicting adverse drug events.
Zhang, Patrick,
"Exploring the Potential of Direct-To-Consumer Genomic Test Data for Predicting Adverse Drug Events"
(2018).
Engineering Theses and Dissertations.
Brown Digital Repository. Brown University Library.
https://doi.org/10.26300/z6n9-xd36
